Understanding how certain medications cause kidney damage
The role of NFkB in calcineurin inhibitor-induced renal fibrosis
['FUNDING_FELLOWSHIP'] · WRIGHT STATE UNIVERSITY · NIH-10906319
This study is looking at how certain medications used to prevent organ rejection in transplant patients can sometimes harm the kidneys over time, and it aims to understand the reasons behind this damage so that better treatments can be developed to keep your kidneys healthy.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WRIGHT STATE UNIVERSITY (nih funded) |
| Locations | 1 site (DAYTON, UNITED STATES) |
| Trial ID | NIH-10906319 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of calcineurin inhibitors, which are medications used to prevent organ rejection in transplant patients and treat certain autoimmune conditions. While these drugs are effective, they can lead to kidney damage over time, specifically renal fibrosis, which can worsen kidney function. The study aims to uncover the molecular mechanisms behind this damage, focusing on the role of specific proteins and signaling pathways that may contribute to kidney injury. By identifying these pathways, the research hopes to pave the way for new therapeutic strategies to protect the kidneys from damage caused by these medications.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients undergoing treatment with calcineurin inhibitors for conditions like organ transplantation or lupus nephritis.
Not a fit: Patients who are not using calcineurin inhibitors or those with unrelated kidney conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent kidney damage in patients using calcineurin inhibitors.
How similar studies have performed: While the specific mechanisms being studied are novel, previous research has shown that understanding drug-induced kidney damage can lead to significant advancements in patient care.
Where this research is happening
DAYTON, UNITED STATES
- WRIGHT STATE UNIVERSITY — DAYTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: UME, ADAKU — WRIGHT STATE UNIVERSITY
- Study coordinator: UME, ADAKU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.